Value of combined application of high risk human papillomavirus DNAdetection and thinprep cytologic test for cervical cancer screening
10.3969/j.issn.1005-1678.2017.01.085
- VernacularTitle:高危型HPV-DNA联合液基细胞学检测对宫颈癌筛查的价值
- Author:
Leilei SUN
;
Shaotiao LI
;
Xingyuan LIN
- Keywords:
TCT;
HR-HPV-DNA;
cervical biopsy;
cervical cancer;
screening
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(1):283-285
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the diagnostic value of thinprep cytologic test (TCT) combined with high-risk human papillomavirus (HR-HPV) DNA for cervical cancer (CC). Methods 141 cases of patients with abnormal cervical lesions were abnormal examined by TCT and were graded by the results of TCT and cervical biopsy, the HR-HPV-DNA was detected by surface plasmon resonance (SPR). Results The cervical biopsy positive rate 65.2% (92/141) was significantly higher than the positive rate of TCT 39.0% (55/141) (χ2=19.45, P < 0.05). The positive rate of HR-HPV-DNA was 66.0% (93/141) was significantly higher than the positive rate of TCT 39.0% (55/141), (χ2=20.53, P < 0.05). Conclusion TCT, HR-HPV-DNA and cervical biopsy are important clinical diagnostic methods for cervical lesions, combine detection of TCT and HR-HPV-DNA can improve the detection rate of cervical lesions.
